CA2708549C - Bmp mutants with decreased susceptibility to noggin - Google Patents
Bmp mutants with decreased susceptibility to noggin Download PDFInfo
- Publication number
- CA2708549C CA2708549C CA2708549A CA2708549A CA2708549C CA 2708549 C CA2708549 C CA 2708549C CA 2708549 A CA2708549 A CA 2708549A CA 2708549 A CA2708549 A CA 2708549A CA 2708549 C CA2708549 C CA 2708549C
- Authority
- CA
- Canada
- Prior art keywords
- bmp
- modified
- amino acid
- wild
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000045246 noggin Human genes 0.000 title claims abstract description 213
- 108700007229 noggin Proteins 0.000 title claims abstract description 213
- 230000003247 decreasing effect Effects 0.000 title description 6
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 396
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 396
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 391
- 102000008154 Bone Morphogenetic Protein 6 Human genes 0.000 claims abstract description 137
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims abstract description 137
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 132
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 124
- 230000005764 inhibitory process Effects 0.000 claims abstract description 89
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 307
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 306
- 238000006467 substitution reaction Methods 0.000 claims description 211
- 235000001014 amino acid Nutrition 0.000 claims description 208
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 167
- 235000018102 proteins Nutrition 0.000 claims description 121
- 150000001413 amino acids Chemical class 0.000 claims description 95
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 56
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 56
- 210000000988 bone and bone Anatomy 0.000 claims description 56
- 102200160798 rs5122 Human genes 0.000 claims description 45
- 102220344807 c.193T>A Human genes 0.000 claims description 43
- 102220034160 rs113842820 Human genes 0.000 claims description 40
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 34
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 33
- 235000018417 cysteine Nutrition 0.000 claims description 32
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 32
- 210000004899 c-terminal region Anatomy 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102200124656 rs6267 Human genes 0.000 claims description 25
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 claims description 24
- 108010090250 Growth Differentiation Factor 6 Proteins 0.000 claims description 23
- 102220055260 rs140446520 Human genes 0.000 claims description 23
- 230000004069 differentiation Effects 0.000 claims description 22
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 21
- 101710204283 Growth/differentiation factor 7 Proteins 0.000 claims description 19
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 claims description 19
- 230000012010 growth Effects 0.000 claims description 19
- 102220144494 rs200079698 Human genes 0.000 claims description 18
- 210000000845 cartilage Anatomy 0.000 claims description 14
- 230000008439 repair process Effects 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 10
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 9
- 102000046095 human BMP6 Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000035118 modified proteins Human genes 0.000 claims description 7
- 108091005573 modified proteins Proteins 0.000 claims description 7
- 102220515504 Interferon gamma_K29Q_mutation Human genes 0.000 claims description 6
- 102220509305 Small integral membrane protein 10_D34Q_mutation Human genes 0.000 claims description 6
- 102220238245 rs1555952639 Human genes 0.000 claims description 6
- 102220005146 rs35262412 Human genes 0.000 claims description 6
- 102220064893 rs35669569 Human genes 0.000 claims description 6
- 102200097281 rs35807406 Human genes 0.000 claims description 6
- 102200105532 rs397509387 Human genes 0.000 claims description 6
- 102220001969 rs696217 Human genes 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 102220520196 Barrier-to-autointegration factor_L50K_mutation Human genes 0.000 claims description 5
- 102200079013 rs1554763777 Human genes 0.000 claims description 5
- 102200118306 rs33919924 Human genes 0.000 claims description 5
- 102220273513 rs373435521 Human genes 0.000 claims description 5
- 102220478560 Apoptosis regulator Bcl-2_D36S_mutation Human genes 0.000 claims description 4
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims description 4
- 102220426871 c.117G>C Human genes 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102200009943 rs116840808 Human genes 0.000 claims description 4
- 102200068503 rs121964997 Human genes 0.000 claims description 4
- 102220478542 Apoptosis regulator Bcl-2_E53A_mutation Human genes 0.000 claims description 3
- 102220520197 Barrier-to-autointegration factor_V51E_mutation Human genes 0.000 claims description 3
- 102220530630 Beta-galactosidase_L57M_mutation Human genes 0.000 claims description 3
- 102220485589 CHRNA7-FAM7A fusion protein_Q41A_mutation Human genes 0.000 claims description 3
- 102220550869 Fumarate hydratase, mitochondrial_N29Q_mutation Human genes 0.000 claims description 3
- 102220504907 Galanin receptor type 1_S67A_mutation Human genes 0.000 claims description 3
- 102220580969 Induced myeloid leukemia cell differentiation protein Mcl-1_Y46Y_mutation Human genes 0.000 claims description 3
- 102220466759 Olfactory receptor 13C5_L69M_mutation Human genes 0.000 claims description 3
- 102220642088 Prolactin-inducible protein_V26L_mutation Human genes 0.000 claims description 3
- 102220493338 Sodium/calcium exchanger 3_H39A_mutation Human genes 0.000 claims description 3
- 102220345409 c.147A>C Human genes 0.000 claims description 3
- 102200097256 rs199473492 Human genes 0.000 claims description 3
- 102220142876 rs200087565 Human genes 0.000 claims description 3
- 102220005517 rs33931984 Human genes 0.000 claims description 3
- 102200005620 rs34282046 Human genes 0.000 claims description 3
- 102220010866 rs397514631 Human genes 0.000 claims description 3
- 102220044659 rs587781460 Human genes 0.000 claims description 3
- 102220203572 rs6926224 Human genes 0.000 claims description 3
- 102220289725 rs778831047 Human genes 0.000 claims description 3
- 102200089536 rs854560 Human genes 0.000 claims description 3
- 102220504701 Galanin receptor type 1_S77A_mutation Human genes 0.000 claims 9
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims 3
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 2
- 102220310822 rs1186663823 Human genes 0.000 claims 2
- 102220546737 Coiled-coil domain-containing protein 24_D55E_mutation Human genes 0.000 claims 1
- 102220504814 Galanin receptor type 1_V35I_mutation Human genes 0.000 claims 1
- 102220495230 Sodium channel subunit beta-2_K38Q_mutation Human genes 0.000 claims 1
- 102220318682 rs1399431033 Human genes 0.000 claims 1
- 102220112531 rs2240308 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 33
- 102000037280 Growth Differentiation Factor 2 Human genes 0.000 abstract description 32
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 abstract description 31
- 239000000203 mixture Substances 0.000 abstract description 27
- 239000005557 antagonist Substances 0.000 abstract description 23
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 82
- 230000000875 corresponding effect Effects 0.000 description 80
- 230000000694 effects Effects 0.000 description 71
- 230000004048 modification Effects 0.000 description 54
- 238000012986 modification Methods 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 37
- 239000007943 implant Substances 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 239000011159 matrix material Substances 0.000 description 23
- 102000012966 Growth Differentiation Factor 5 Human genes 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 230000004927 fusion Effects 0.000 description 21
- 102000008152 Bone Morphogenetic Protein 5 Human genes 0.000 description 20
- 102000012972 Growth Differentiation Factor 6 Human genes 0.000 description 20
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 102220506390 Protein PBDC1_S77C_mutation Human genes 0.000 description 16
- 230000008468 bone growth Effects 0.000 description 16
- 239000013604 expression vector Substances 0.000 description 15
- 230000002188 osteogenic effect Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 239000011324 bead Substances 0.000 description 14
- 230000037118 bone strength Effects 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 12
- 239000003636 conditioned culture medium Substances 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- -1 TGF-I3 Proteins 0.000 description 11
- 230000007547 defect Effects 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 description 10
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 description 10
- 238000007429 general method Methods 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000011164 ossification Effects 0.000 description 8
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 7
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 7
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000017423 tissue regeneration Effects 0.000 description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000038900 DAN family Human genes 0.000 description 5
- 108091065053 DAN family Proteins 0.000 description 5
- 102100033808 Glycoprotein hormone alpha-2 Human genes 0.000 description 5
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 5
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 5
- 101001069261 Homo sapiens Glycoprotein hormone alpha-2 Proteins 0.000 description 5
- 101150047694 ID1 gene Proteins 0.000 description 5
- 102220534852 Kinesin-like protein KIF22_R48A_mutation Human genes 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 108010008846 chordin Proteins 0.000 description 5
- 102000006533 chordin Human genes 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 102220285580 rs1554888119 Human genes 0.000 description 5
- 238000002821 scintillation proximity assay Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 241000202252 Cerberus Species 0.000 description 4
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 4
- 101150118570 Msx2 gene Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 108091005682 Receptor kinases Proteins 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002648 chondrogenic effect Effects 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 102000046041 human GDF2 Human genes 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940076372 protein antagonist Drugs 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 102200158796 rs35885783 Human genes 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000025934 tissue morphogenesis Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102100037150 BMP and activin membrane-bound inhibitor homolog Human genes 0.000 description 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 2
- 101710120270 Bone morphogenetic protein receptor type-1A Proteins 0.000 description 2
- 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 2
- 102220499104 Cytosol aminopeptidase_L51K_mutation Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102100029379 Follistatin-related protein 3 Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 102100038353 Gremlin-2 Human genes 0.000 description 2
- 101710169778 Gremlin-2 Proteins 0.000 description 2
- 102000000594 Growth Differentiation Factor 10 Human genes 0.000 description 2
- 108010041881 Growth Differentiation Factor 10 Proteins 0.000 description 2
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 101000740070 Homo sapiens BMP and activin membrane-bound inhibitor homolog Proteins 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 2
- 101001062529 Homo sapiens Follistatin-related protein 3 Proteins 0.000 description 2
- 102220534831 Kinesin-like protein KIF22_D55A_mutation Human genes 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102000011830 Neural cell adhesion Human genes 0.000 description 2
- 108050002172 Neural cell adhesion Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102220526990 Tumor protein D54_K38Q_mutation Human genes 0.000 description 2
- 102000010571 Type II Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- 108010063130 Type II Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000868 anti-mullerian hormone Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000034127 bone morphogenesis Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000003271 compound fluorescence assay Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 102000045896 human BMP2 Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 238000013289 male long evans rat Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 102220282682 rs1060502587 Human genes 0.000 description 2
- 102200093891 rs1869780 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- 102220497106 5-hydroxytryptamine receptor 3B_I57A_mutation Human genes 0.000 description 1
- 101150080498 ALP gene Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 102220486151 Alpha-galactosidase A_M72V_mutation Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102220468481 Annexin A2_S26E_mutation Human genes 0.000 description 1
- 102220467201 Aquaporin-2_A70D_mutation Human genes 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- 102100025440 BMP-binding endothelial regulator protein Human genes 0.000 description 1
- 102220488053 BMP-binding endothelial regulator protein_D32S_mutation Human genes 0.000 description 1
- 238000012492 Biacore method Methods 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 101710117970 Bone morphogenetic protein 8B Proteins 0.000 description 1
- 102220488099 Bone morphogenetic protein receptor type-1A_F58Y_mutation Human genes 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 102220568693 Claudin-16_H71D_mutation Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102220545278 Desmoglein-1_S24E_mutation Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102100020921 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 1
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 1
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 1
- 101710204270 Growth/differentiation factor 2 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102220632167 Histone-lysine N-trimethyltransferase SMYD5_N65Y_mutation Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000934632 Homo sapiens BMP-binding endothelial regulator protein Proteins 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 1
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 1
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102220547188 Immunoglobulin heavy constant alpha 1_N299D_mutation Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102220465478 Insulin-like growth factor II_R48E_mutation Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102220487447 Isoaspartyl peptidase/L-asparaginase_D54R_mutation Human genes 0.000 description 1
- 102220534856 Kinesin-like protein KIF22_R48K_mutation Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102220512181 Max-interacting protein 1_I57D_mutation Human genes 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102220520996 N-chimaerin_D54T_mutation Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102220486919 Nucleosome-remodeling factor subunit BPTF_V28I_mutation Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 102220642086 Prolactin-inducible protein_S46N_mutation Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102220576894 Protein BUD31 homolog_R48D_mutation Human genes 0.000 description 1
- 102220622450 Protein Hook homolog 3_F40Y_mutation Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000015864 Protobothrops flavoviridis Species 0.000 description 1
- 102220612258 Putative uncharacterized protein PIK3CD-AS1_H54D_mutation Human genes 0.000 description 1
- 102220522980 RNA 5'-monophosphate methyltransferase_N76A_mutation Human genes 0.000 description 1
- 102220599096 Ras-related protein Rab-1B_Y78D_mutation Human genes 0.000 description 1
- 102220473730 Ras-related protein Rab-5A_A56E_mutation Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102220511953 Replication protein A 70 kDa DNA-binding subunit_R41E_mutation Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102220509535 SMAD5 antisense gene protein 1_D47S_mutation Human genes 0.000 description 1
- 101001059240 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Site-specific recombinase Flp Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 101710169324 Sclerostin domain-containing protein 1 Proteins 0.000 description 1
- 102100022432 Sclerostin domain-containing protein 1 Human genes 0.000 description 1
- 102220492441 Selenoprotein V_F43Y_mutation Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 102220502295 Sodium/calcium exchanger 3_D24N_mutation Human genes 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102220608208 TYRO protein tyrosine kinase-binding protein_N69A_mutation Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102220559475 Transmembrane protein 207_L57V_mutation Human genes 0.000 description 1
- 102100031904 Tumor protein D54 Human genes 0.000 description 1
- 208000004608 Ureteral Obstruction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 102220506801 Vitelline membrane outer layer protein 1 homolog_N73T_mutation Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940005553 analgesics and anesthetics Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 102220359602 c.121C>G Human genes 0.000 description 1
- 102220353958 c.134A>G Human genes 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007355 cartilage morphogenesis Effects 0.000 description 1
- 108010027904 cartilage-derived-morphogenetic protein-2 Proteins 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 108010045487 coagulogen Proteins 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000013860 dentinogenesis Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000029600 embryonic pattern specification Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000046148 human BMP4 Human genes 0.000 description 1
- 102000046096 human BMP5 Human genes 0.000 description 1
- 102000046107 human BMP7 Human genes 0.000 description 1
- 102000046039 human GDF5 Human genes 0.000 description 1
- 102000053737 human GDF6 Human genes 0.000 description 1
- 102000048885 human GDF7 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000982 limb bud Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 1
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001896 polybutyrate Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 108091008597 receptor serine/threonine kinases Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102200087972 rs1042821 Human genes 0.000 description 1
- 102200010360 rs1057520644 Human genes 0.000 description 1
- 102200149764 rs118204087 Human genes 0.000 description 1
- 102200041248 rs1233331806 Human genes 0.000 description 1
- 102200081898 rs137854512 Human genes 0.000 description 1
- 102220163982 rs149878562 Human genes 0.000 description 1
- 102200029981 rs28936700 Human genes 0.000 description 1
- 102200082887 rs33950093 Human genes 0.000 description 1
- 102200118256 rs33969400 Human genes 0.000 description 1
- 102200082810 rs33980484 Human genes 0.000 description 1
- 102200118211 rs33991294 Human genes 0.000 description 1
- 102220022693 rs386833839 Human genes 0.000 description 1
- 102200037023 rs387907270 Human genes 0.000 description 1
- 102220064265 rs531598856 Human genes 0.000 description 1
- 102220047519 rs587777841 Human genes 0.000 description 1
- 102220269348 rs61747367 Human genes 0.000 description 1
- 102220082345 rs747846279 Human genes 0.000 description 1
- 102220241914 rs771007866 Human genes 0.000 description 1
- 102220067420 rs778414770 Human genes 0.000 description 1
- 102220168988 rs781108007 Human genes 0.000 description 1
- 102220059219 rs786202857 Human genes 0.000 description 1
- 102220009751 rs80358454 Human genes 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US875407P | 2007-12-21 | 2007-12-21 | |
| US61/008,754 | 2007-12-21 | ||
| PCT/US2008/087720 WO2009086131A1 (en) | 2007-12-21 | 2008-12-19 | Bmp mutants with decreased susceptibility to noggin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2708549A1 CA2708549A1 (en) | 2009-07-09 |
| CA2708549C true CA2708549C (en) | 2014-04-01 |
Family
ID=40424155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2708549A Expired - Fee Related CA2708549C (en) | 2007-12-21 | 2008-12-19 | Bmp mutants with decreased susceptibility to noggin |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110039773A1 (enExample) |
| EP (1) | EP2222696A1 (enExample) |
| JP (2) | JP5529754B2 (enExample) |
| AU (1) | AU2008345689B2 (enExample) |
| CA (1) | CA2708549C (enExample) |
| WO (1) | WO2009086131A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1698691A1 (en) * | 2005-03-04 | 2006-09-06 | Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH | Growth factor mutants with improved biological activity |
| EP2222696A1 (en) * | 2007-12-21 | 2010-09-01 | Stryker Corporation | Bmp mutants with decreased susceptibility to noggin |
| JP5749659B2 (ja) * | 2009-03-12 | 2015-07-15 | ハーゼ インベストメンツ ウーゲー | Ｂｍｐアンタゴニスト感受性が低下した骨形成タンパク質２（ｂｍｐ２）変異体 |
| EP2516456A1 (en) * | 2009-12-22 | 2012-10-31 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
| AU2015202418B2 (en) * | 2010-08-20 | 2017-02-02 | Wyeth Llc | Designer osteogenic proteins |
| CA2807343C (en) | 2010-08-20 | 2018-05-22 | Wyeth Llc | Designer osteogenic proteins |
| US9856305B2 (en) | 2010-08-20 | 2018-01-02 | Wyeth Llc | Designer osteogenic proteins |
| US9688735B2 (en) * | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| EP2784083A1 (en) * | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| EP3171886A4 (en) * | 2014-07-21 | 2018-01-24 | The Arizona Board of Regents On Behalf of the University of Arizona | Ang-(1-7) derviative oligopeptides and methods for using and producing the same |
| CA2976376A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| PL3288379T3 (pl) | 2015-05-01 | 2022-03-07 | Onl Therapeutics, Inc. | Kompozycje peptydowe i sposoby stosowania |
| US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| MX2019012871A (es) | 2017-04-27 | 2021-01-08 | Lilly Co Eli | Variantes de proteina morfogenica osea humana 7 (bmp7). |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026713A1 (de) * | 2000-05-30 | 2001-12-06 | Walter Sebald | Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta |
| JP2008500816A (ja) * | 2004-03-31 | 2008-01-17 | ゼンコー・インコーポレイテッド | 改善された性質を有するｂｍｐ−７変異体 |
| CA2567805A1 (en) * | 2004-05-27 | 2005-12-15 | Acceleron Pharma Inc. | Tgf derepressors and uses related thereto |
| WO2008051526A2 (en) * | 2006-10-23 | 2008-05-02 | Stryker Corporation | Bone morphogenetic proteins |
| EP2222696A1 (en) * | 2007-12-21 | 2010-09-01 | Stryker Corporation | Bmp mutants with decreased susceptibility to noggin |
-
2008
- 2008-12-19 EP EP08867546A patent/EP2222696A1/en not_active Withdrawn
- 2008-12-19 WO PCT/US2008/087720 patent/WO2009086131A1/en not_active Ceased
- 2008-12-19 AU AU2008345689A patent/AU2008345689B2/en not_active Ceased
- 2008-12-19 US US12/746,821 patent/US20110039773A1/en not_active Abandoned
- 2008-12-19 CA CA2708549A patent/CA2708549C/en not_active Expired - Fee Related
- 2008-12-19 JP JP2010539882A patent/JP5529754B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-30 US US13/690,211 patent/US20130184208A1/en not_active Abandoned
-
2014
- 2014-03-19 JP JP2014056688A patent/JP2014121334A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009086131A4 (en) | 2009-09-11 |
| AU2008345689B2 (en) | 2013-04-18 |
| WO2009086131A1 (en) | 2009-07-09 |
| US20110039773A1 (en) | 2011-02-17 |
| JP2011507903A (ja) | 2011-03-10 |
| AU2008345689A1 (en) | 2009-07-09 |
| CA2708549A1 (en) | 2009-07-09 |
| EP2222696A1 (en) | 2010-09-01 |
| JP5529754B2 (ja) | 2014-06-25 |
| US20130184208A1 (en) | 2013-07-18 |
| JP2014121334A (ja) | 2014-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2708549C (en) | Bmp mutants with decreased susceptibility to noggin | |
| TWI444475B (zh) | 經設計之成骨蛋白類 | |
| DE69333745T2 (de) | Löslicher komplex morphogener proteine und zusammensetzungen davon | |
| WO2008051526A9 (en) | Bone morphogenetic proteins | |
| US11008373B2 (en) | Designer osteogenic proteins | |
| US20130190236A1 (en) | BMP-7 Variants with Reduced Immunogenicity | |
| AU2015202418B2 (en) | Designer osteogenic proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20161219 |